Magazine Article | March 7, 2018

Inspiring Trust In Industry Practices

Source: Life Science Leader

By Suresh Kumar

Current drug pricing is a mainstream issue that cannot be expediently blamed on fringe players or obfuscated by participants across the healthcare delivery chain, or by any of them blaming the others. The issue of price and affordability must be addressed by what is now perceived as a status-quo-happy healthcare industry.

Let’s look at the relentless focus on healthcare costs through the lens of Sovaldi (see box) which, at $1,000 per pill, galvanized voter sentiment across party lines, to underscore the growing divergence between industry practices and commercial principles.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: